Katrina Kaiser

213-821-2311
email

Katrina M. Kaiser is a SAS Research Programmer for the USC Schaeffer Center, and her current projects focus on Medicare data. Before joining the Schaeffer Center, she was an employment litigation consultant at Resolution Economics, where she specialized in modeling the demographics of different labor markets for discrimination-related matters. She earned her MA and BA in Economics from USC in 2014, and is currently enrolled in USC’s Geographic Information Science and Technology (GIST) Certificate Program.

Recent Work

Cancer Drug Trastuzumab And Its Biosimilars Compete On Price For Market Share

Using Medicare claims, Schaeffer experts documented US prescribing patterns for originator biologic trastuzumab (Herceptin), a targeted cancer therapy, and five biosimilar entrants since 2019.
Categorized in
- Research
- Journal Articles
Reforming the Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government

Researchers evaluate prescription drug claims from Medicare Part D beneficiaries to evaluate the current spending distribution.
Categorized in
- Research
- Journal Articles
The Protocol of Improving Safe Antibiotic Prescribing in Telehealth: A Randomized Trial

o better understand how best to decrease inappropriate antibiotic prescribing for ARIs in telehealth, we are conducting a large randomized quality improvement trial testing both patient- and physician-facing feedback and behavioral nudges embedded in the electronic health record.
Categorized in
- Research
- Journal Articles
How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?

If cost-sharing were based on net price it would provide meaningful financial relief to many Part D beneficiaries.
Categorized in

Katrina Kaiser's contact information

Katrina Kaiser's Bio

Recent Work

Cancer Drug Trastuzumab And Its Biosimilars Compete On Price For Market Share

Reforming the Medicare Part D Benefit Design: Financial Implications for Beneficiaries, Private Plans, Drug Manufacturers, and the Federal Government

The Protocol of Improving Safe Antibiotic Prescribing in Telehealth: A Randomized Trial

How Would Sharing Rebates at the Point-Of-Sale Affect Beneficiary Cost-Sharing in Medicare Part D?